Without the right medication, amyloidosis patients may experience irreversible disease progression or a decreased quality of life.

New, innovative treatment options can help patients with a rare condition called hATTR amyloidosis. Patients can now be treated with infusions, injections, and oral medications. And more innovation is coming.

But amyloidosis patients can’t always access the treatment they need.

Some insurers:

- Limit access through utilization management
- Require excessive out-of-pocket costs
- Refuse to cover treatment

Patients need access to the full range of treatments for hATTR amyloidosis.